7th Annual Association for Bariatric Endoscopy (ABE) Meeting: Comprehensive Care of the Patient with Obesity – Endoscopy and Beyond! | May 2022-Imagineering the Future of EBTs-GastricandSmall Bowel Therapies

Pdf Summary

The document discusses the future of EBTs (gastric and small bowel therapies) for weight loss and metabolic improvements. The author mentions current goals for available EBTs, such as safety, efficacy in weight loss, repeatability, and reversibility without compromising future bariatric surgery. However, they question whether these benchmarks, set 10 years ago, are still appropriate. There is emerging evidence that the risk-benefit profile for surgery is favorable for patients with a BMI of 30-40 and even 25-30 in patients with diabetes.<br /><br />The document highlights various EBTs and their outcomes. These include pharmaceutical therapy, intragastric balloons, endoscopic sleeve gastroplasty (ESG), duodenal-jejunal bypass liner (DJBL), and endoscopic magnetic appetite control system. The author presents data on weight loss and metabolic improvements achieved with these therapies. Additionally, they discuss the potential of combining ESG with pharmaceutical therapy for enhanced outcomes.<br /><br />The document emphasizes the need for a deeper understanding of the mechanisms of bariatric surgery to develop EBTs that are well-tolerated, effective, safe, and appealing to patients. The ultimate goals of EBTs are described as having efficacy similar to bariatric surgery, being safer and more cost-effective, and providing long-term improvement in metabolic outcomes.<br /><br />The document also mentions several EBT technologies in development, such as Gelesis100, Jellynov, Glyscend Technology, and endoscopic magnetic appetite control system. These technologies aim to reduce appetite, induce satiety, and promote weight loss through various mechanisms.<br /><br />The author suggests that a personalized approach to EBTs may be necessary, taking into account individual patient factors and preferences. The document concludes by stating that further research and innovation are needed to advance the field of EBTs and improve outcomes for patients with obesity and metabolic diseases.

Asset Subtitle

Vivek Kumbhari, MD

Keywords

EBTs

weight loss

metabolic improvements

bariatric surgery

safety

efficacy

pharmaceutical therapy

endoscopic sleeve gastroplasty

personalized approach

metabolic diseases